Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Pirfenidone (Primary)
- Indications Interstitial lung diseases
- Focus Therapeutic Use
- Sponsors Roche; Roche Farma
- 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2018 Planned End Date changed from 17 Jan 2020 to 4 Feb 2020.
- 11 Jun 2018 Planned primary completion date changed from 17 Jan 2020 to 4 Feb 2020.